atural Killer cel therapie tegen teruggekeerde eierstokkanker.
- Conditions
- Recurrent ovarian carcinoma, recidief ovarium carcinoom. immunotherapy, immuuntherapie.
- Registration Number
- NL-OMON20648
- Lead Sponsor
- Radboudumc
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 12
Inclusion Criteria
•Patients suffering from their second recurrence of ovarian, fallopian tube or primary peritoneal cancer, with an elevated serum level of CA-125 on two successive time points with 28 days in between, reaching a value of more than 2 times nadir and above 35 U/ml without gastrointestinal symptoms.
•Able to undergo laparoscopic IP port placement and IP treatment administration
Exclusion Criteria
•Patients on immunosuppressive drugs
•Patients with active infections (viral, bacterial or fungal) that requires specific therapy. Acute anti-infectious therapy must have been completed within 14 days prior to study treatment
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety and toxicity of intraperitoneal NK cells.
- Secondary Outcome Measures
Name Time Method In vivo detection and expansion of the transfused UCB-NK cells, detection of biological NK cell activity and effect on CA-125 levels